Application of Volumetric MR Spectroscopic Imaging for Localization of Neocortical Epilepsy

Overview

Journal Epilepsy Res

Specialty Neurology

Date 2009 Nov 21

PMID 19926450

Citations 21

Authors

Andrew A Maudsley

Claudia Domenig

R Eugene Ramsay

Brian C Bowen

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim of this study was to evaluate volumetric proton magnetic resonance spectroscopic imaging (MRSI) for localization of epileptogenic foci in neocortical epilepsy.

Methods: Twenty-five subjects reporting seizures considered to be of neocortical origin were recruited to take part in a 3-T MR study that included high-resolution structural MRI and a whole-brain MRSI acquisition. Using a fully automated MRSI processing protocol, maps for signal intensity normalized N-acetylaspartate (NAA), creatine, and choline were created, together with the relative volume fraction of grey-matter, white-matter, and CSF within each MRSI voxel. Analyses were performed using visual observation of the metabolite and metabolite ratio maps; voxel-based calculation of differences in these metabolite maps relative to normal controls; comparison of average grey-matter and white-matter metabolite values over each lobar volume; and examination of relative left-right asymmetry factors by brain region.

Results: Data from 14 subjects were suitable for inclusion in the analysis. Eight subjects had MRI-visible pathologies that were associated with decreases in NAA/creatine, which extended beyond the volume indicated by the MRI. Five subjects demonstrated no significant metabolic alterations using any of the analysis methods, and one subject had no findings on MRI or MRSI.

Conclusions: This proof of principle study supports previous evidence that alterations of MR-detected brain metabolites can be detected in tissue areas affected by neocortical seizure activity, while additionally demonstrating advantages of the volumetric MRSI approach.

Citing Articles

High-quality lipid suppression and B0 shimming for human brain H MRSI.

Kumaragamage C, McIntyre S, Nixon T, De Feyter H, de Graaf R Neuroimage. 2024; 300:120845.

PMID: 39276817 PMC: 11540284. DOI: 10.1016/j.neuroimage.2024.120845.

Recent Advances in Neuroimaging of Epilepsy.

Goodman A, Szaflarski J Neurotherapeutics. 2021; 18(2):811-826.

PMID: 33942270 PMC: 8423975. DOI: 10.1007/s13311-021-01049-y.

Fast, regional three-dimensional hybrid (1D-Hadamard 2D-rosette) proton MR spectroscopic imaging in the human temporal lobes.

Tal A, Zhao T, Schirda C, Hetherington H, Pan J, Gonen O NMR Biomed. 2021; 34(6):e4507.

PMID: 33754420 PMC: 8122085. DOI: 10.1002/nbm.4507.

Advanced magnetic resonance spectroscopic neuroimaging: Experts' consensus recommendations.

Maudsley A, Andronesi O, Barker P, Bizzi A, Bogner W, Henning A NMR Biomed. 2020; 34(5):e4309.

PMID: 32350978 PMC: 7606742. DOI: 10.1002/nbm.4309.

Maghsudi H, Schutze M, Maudsley A, Dadak M, Lanfermann H, Ding X Clin Neuroradiol. 2019; 30(3):581-589.

PMID: 31350597 PMC: 7276177. DOI: 10.1007/s00062-019-00814-z.

References

Soher B, Young K, Govindaraju V, Maudsley A . Automated spectral analysis III: application to in vivo proton MR spectroscopy and spectroscopic imaging. Magn Reson Med. 1998; 40(6):822-31. DOI: 10.1002/mrm.1910400607. View

Maudsley A, Domenig C, Govind V, Darkazanli A, Studholme C, Arheart K . Mapping of brain metabolite distributions by volumetric proton MR spectroscopic imaging (MRSI). Magn Reson Med. 2008; 61(3):548-59. PMC: 2724718. DOI: 10.1002/mrm.21875. View

Hartman A, Lesser R . Update on epilepsy and cerebral localization. Curr Neurol Neurosci Rep. 2007; 7(6):498-507. DOI: 10.1007/s11910-007-0077-4. View

Smith S, Jenkinson M, Woolrich M, Beckmann C, Behrens T, Johansen-Berg H . Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage. 2004; 23 Suppl 1:S208-19. DOI: 10.1016/j.neuroimage.2004.07.051. View

Laxer K . Clinical applications of magnetic resonance spectroscopy. Epilepsia. 1997; 38 Suppl 4:S13-7. DOI: 10.1111/j.1528-1157.1997.tb04534.x. View

Kuzniecky R, Devinsky O . Surgery Insight: surgical management of epilepsy. Nat Clin Pract Neurol. 2007; 3(12):673-81. DOI: 10.1038/ncpneuro0663. View

Garcia P, Laxer K, van der Grond J, Hugg J, Matson G, Weiner M . Correlation of seizure frequency with N-acetyl-aspartate levels determined by 1H magnetic resonance spectroscopic imaging. Magn Reson Imaging. 1997; 15(4):475-8. DOI: 10.1016/s0730-725x(96)00327-x. View

Leite C, Lucato L, Sato J, Valente K, Otaduy M . Multivoxel proton MR spectroscopy in malformations of cortical development. AJNR Am J Neuroradiol. 2007; 28(6):1071-5. PMC: 8134160. DOI: 10.3174/ajnr.A0511. View

Stanley J, Cendes F, Dubeau F, Andermann F, Arnold D . Proton magnetic resonance spectroscopic imaging in patients with extratemporal epilepsy. Epilepsia. 1998; 39(3):267-73. DOI: 10.1111/j.1528-1157.1998.tb01371.x. View

10.

Zhang Y, Brady M, Smith S . Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging. 2001; 20(1):45-57. DOI: 10.1109/42.906424. View

11.

Haupt C, Schuff N, Weiner M, Maudsley A . Removal of lipid artifacts in 1H spectroscopic imaging by data extrapolation. Magn Reson Med. 1996; 35(5):678-87. PMC: 2733339. DOI: 10.1002/mrm.1910350509. View

12.

Lundbom N, Gaily E, Vuori K, Paetau R, Liukkonen E, Rajapakse J . Proton spectroscopic imaging shows abnormalities in glial and neuronal cell pools in frontal lobe epilepsy. Epilepsia. 2002; 42(12):1507-14. DOI: 10.1046/j.1528-1157.2001.15301.x. View

13.

Maudsley A, Darkazanli A, Alger J, Hall L, Schuff N, Studholme C . Comprehensive processing, display and analysis for in vivo MR spectroscopic imaging. NMR Biomed. 2006; 19(4):492-503. PMC: 2673915. DOI: 10.1002/nbm.1025. View

14.

Guye M, Ranjeva J, Le Fur Y, Bartolomei F, Confort-Gouny S, Regis J . 1H-MRS imaging in intractable frontal lobe epilepsies characterized by depth electrode recording. Neuroimage. 2005; 26(4):1174-83. DOI: 10.1016/j.neuroimage.2005.03.023. View

15.

Goffin K, Dedeurwaerdere S, Van Laere K, Van Paesschen W . Neuronuclear assessment of patients with epilepsy. Semin Nucl Med. 2008; 38(4):227-39. DOI: 10.1053/j.semnuclmed.2008.02.004. View

16.

Kuzniecky R, Hetherington H, Pan J, Hugg J, Palmer C, Gilliam F . Proton spectroscopic imaging at 4.1 tesla in patients with malformations of cortical development and epilepsy. Neurology. 1997; 48(4):1018-24. DOI: 10.1212/wnl.48.4.1018. View

17.

Li L, Cendes F, Andermann F, Dubeau F, Arnold D . Spatial extent of neuronal metabolic dysfunction measured by proton MR spectroscopic imaging in patients with localization-related epilepsy. Epilepsia. 2000; 41(6):666-74. DOI: 10.1111/j.1528-1157.2000.tb00226.x. View

18.

Moffett J, Ross B, Arun P, Madhavarao C, Namboodiri A . N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol. 2007; 81(2):89-131. PMC: 1919520. DOI: 10.1016/j.pneurobio.2006.12.003. View

19.

Krsek P, Hajek M, Dezortova M, Jiru F, Skoch A, Marusic P . (1)H MR spectroscopic imaging in patients with MRI-negative extratemporal epilepsy: correlation with ictal onset zone and histopathology. Eur Radiol. 2007; 17(8):2126-35. DOI: 10.1007/s00330-007-0594-1. View

20.

Maudsley A, Domenig C, Sheriff S . Reproducibility of serial whole-brain MR spectroscopic imaging. NMR Biomed. 2009; 23(3):251-6. PMC: 2917802. DOI: 10.1002/nbm.1445. View